Three papers recently published in Nature Medicine provide the most detailed analyses of fetal midbrain grafts in patients with Parkinson's disease. Some of the results are surprising and suggest a new wave of questions aimed at both the value of cell therapy and the nature of the disease itself.
For a long time,.transplantation.was frowned upon.. So deep-seated, however, and of such long standing is the human preference for being alive that these spokesmen have not carried their point.
-P.B. Medawar and J.S. Medawar, Aristotle to Zoos, Harvard University Press, 1983 Approximately one million, mostly elderly, Americans suffer from Parkinson's disease (PD), and as many as three million more have yet to be diagnosed. PD causes the degeneration of the midbrain dopamine neurons controlling movement and gait. Although the movement disorder is an obvious outward sign, the disease involves a more widespread dysfunction and degeneration. Many of the motor symptoms can be treated for several years with L-DOPA, which is readily converted to dopamine by the remaining dopamine neurons. Eventually, nearly all of the dopamine neurons succumb to the degenerative process, and patients become unresponsive to L-DOPA. Because of the important role of dopamine neurons, there has been extensive interest in the idea that diseased cells might be replaced by transplantation.
Cell therapies for PD currently use fetal midbrain precursors, and, because access to fetal tissue is limited, pluripotent stem cells are seen as a source of dopamine neurons in the future. The first transplants of fetal midbrain tissue into Parkinson's disease patients were performed almost 2 decades ago. These surgeries appear to cause an improvement in motor function, lasting several years.
However, more recent clinical trials failed to support the original interpretation, raising doubts about the merit of cell therapy in the clinical setting. Three recent papers analyze the brains of eight PD patients who received grafts of human fetal midbrain tissue 9-16 years earlier (Kordower et al., 2008; Li et al., 2008; Mendez et al., 2008) . The grafts show concerning features, including the inappropriate presence of serotonin neurons, low levels of the plasma membrane transporter that regulates dopamine function, and the presence of Lewy bodies that are thought to mark diseased tissue.
Specifically, in two of the studies, Lewy bodies are found within the graft. Kordower et al. describe a woman who received bilateral transplants after suffering with PD for 22 years. Although transplantation remedied the disease, she began to re-experience motor problems 11 years later. She died of cardiac arrest, presumably unrelated to PD, 14 years after transplantation and 3 years after her parkinsonian symptoms resurfaced. Li et al. describe two individuals who received two separate transplants, one to each hemisphere. These patients died 16/12 (left side/right side) and 13/11 (left side/ right side) years after transplantation. All three of these patients in the studies of Kordower et al. and Li et al. developed Lewy bodies within the grafted tissue. In contrast, Mendez et al. performed postmortem analysis on the brains of five patients who had been transplanted between 9 and 14 years earlier. Unlike Kordower et al. and Li et al., Mendez et al. were unable to find any Lewy body pathology within the grafts in these patients. All together, three out of eight brains transplanted for 9+ years contained Lewy bodies within the grafts. While the number of brains analyzed is small, these studies suggest that the development of Lewy body pathology is not uncommon in fetal midbrain grafts. Still, these results also suggest that fetal midbrain grafts can remain unaffected by Lewy bodies for a decade or more, which would be meaningful, particularly for L-DOPA-unresponsive patients. It is clear that the transplantation of dopamine neurons into human beings has not yet been optimized.
The uncertain clinical prospects for cell therapy contrast with scientific and political forces that are generating a wide interest in dopamine neurons. On the scientific side of this dialectic, there is increasing information about the origin of dopamine neurons in normal mammalian development and in the virtual development made possible by pluripotent stem cell technologies. Funding institutions around the world are supporting a major investment based on this technology, but the same issue of Nature Medicine that reports the graft pathology also contains a strong attack on the premise that cell transplantation is a suitable approach to PD (Braak and Del Tredici, 2008) . The most significant finding, observed in two of the papers, is the identification of ubiquitin and a-synuclein-immunoreactive subcellular aggregates that resemble Lewy bodies (Li et al., 2008; Kordower et al., 2008) . In their commentary, Braak and Del Tredici argue that the disease pathology in the grafts strengthens the view that cell therapies in PD are not likely to work. Their main point is that transplantation does not address the root cause of a disease that is initiated elsewhere and only affects dopamine neurons when widespread damage in other regions is already underway.
Lewy bodies are protein aggregates found in some but not all patients with Parkinson's disease and with other neurodegenerative disease. Lewy bodies contain a-synuclein, neurofilament, crystallin, and proteins of the proteasome. a-synuclein holds a special place in our understanding of PD because mutations in this gene provided the first example of a genetic cause of PD. a-synuclein is associated with synaptic vesicles in wide regions of the brain, and mice expressing mutant a-synuclein develop Lewy bodies. a-synuclein pathologies are also associated with other brain diseases in a complex manner. Even within a single kindred, a-synuclein mutation can cause a parkinsonian outcome alongside very different brain diseases (Singleton et al., 2003) . In PD patients, Lewy bodies are commonly found in midbrain dopamine neurons and, importantly, in other neurons. Lewy body pathology is used to define the progression of PD and suggests that other cells are affected before dopamine neurons (see Braak and Del Tredici, 2008) . It follows that the disease is not a cell-autonomous problem in dopamine neurons and that therapies are needed that address damage to other brain regions.
The idea that neurodegeneration is not a simple cell-autonomous problem is supported by studies of other diseases. Amyotrophic lateral sclerosis (ALS) is characterized by a progressive loss of motor neurons, and a small percentage of ALS cases are associated with mutations in the superoxide dismutase 1 (SOD1) gene. Transgenic and mutant mice misexpressing disease-causing SOD1 proteins show motor neuron degeneration and motor difficulties seen in ALS. When the mutant SOD1 specifically is expressed in motor neurons, they degenerate. More surprising is the observation that reducing the expression of mutant SOD1 in astrocytes slows the progression of motor neuron degeneration. Consistent with this finding, in vitro experiments show that glia expressing mutant SOD1 induce cell death in cocultured ES cell-derived motor neurons, regardless of the genotype of the motor neurons. A recent study with chimeric mice suggests that ALS is initiated by mutant SOD1 expressed in cells other than motor neurons (Yamanaka et al., 2008;  this reference includes citations to many of the other observations discussed here). Studies with mouse mutants and bone marrow transplantation suggest an involvement of microglia in motor neuron degeneration. A role for microglia in SOD1-induced motor neuron loss is supported by fractalkine receptor mutants. Fractalkine is a chemokine (CX3CL1) that protects motor neurons from the damaging effects of the SOD1 G93A mutation by inhibiting inflammatory responses (Cardona et al., 2006) . The loss of neurotrophic factors generated by the vascular system has also been suggested as a cause for ALS. The conditional deletion of vascular endothelial growth factor (VEGF) leads to the degeneration of motor neurons, and genetic variants in the VEGF and angiogenin, another related factor that regulates endothelial cells, are associated with the development of ALS (Greenway et al., 2006) . These results suggest that interactions between cells of the immune, vascular, and nervous systems regulate initiation and progression of ALS. Huntington's disease (HD) is an autosomal-dominant disease where loss of striatal neurons is a major feature of the symptoms. The protein mutated in HD, huntingtin, has been shown to regulate levels of the neurotrophic factor BDNF, and cortical levels of BDNF protein are low in the brains of HD patients. BDNF expressed in layer V/VI cortical pyramidal neurons is delivered to the striatum by anterograde transport, but the deficit in HD may start in a cortical interneuron (Gu et al., 2005) . Like HD, the spinocerebellar ataxias (SCA) are caused by mutations that result from polyglutamine (polyQ) expansion. There are six forms of SCA caused by polyQ expansion in different proteins. When the repeat lengths are low, the diseases appear distinct, but the pathologies overlap with increasing copies of the triplet repeat (Orr and Zoghbi, 2007) . SCA1 is caused by mutation in ataxin 1 that leads to degeneration of Purkinje cells. Remarkably, studies in mice show that the toxicity results from ''hit-and-run'' expression of the mutant during Purkinje cell development (Orr and Zoghbi, 2007) . As these experiments show, understanding cell interactions in space and time will play an important role in our understanding of polyQ-dependent neuron loss.
With these data in mind, let's return to PD. Although little is known about the mechanisms responsible for the initiation of PD, mutations have been identified that are thought to cause Parkinson's disease in a small number of cases. The identification of PARK genes, including a-synuclein, has provided many new insights into disease progression. However, PARK gene expression is not limited to dopamine neurons and, as Braak and Del Tredici stress, other cells show pathology at early stages of PD. In addition to the involvement of other neurons, there is strong evidence for ongoing immune system involvement in the substantia nigra of PD patients and in disease models (McGeer and McGeer, 2004) . A remarkable accident where individuals were briefly exposed to the toxin MPTP shows a long-lasting sensitivity of dopamine neurons (Langston et al. 1999) . These results suggest that a transient insult may trigger a diseased state involving multiple cell types in the midbrain that also disrupts other brain regions.
The case reports and the welcome frank tone of the commentary on grafted PD patients encourage stem cell researchers to attend to the distributed pathology of this devastating illness. It would be hard to justify the current interest in deriving dopamine neurons from stem cells to treat a disease triggered and sustained by ongoing pathology in other cell types. However, there are two good reasons to believe that interest in the production of dopamine neurons from stem cells will not diminish but grow. The first is the clear evidence that stem cell-derived dopamine neurons function in vivo (Kim et al., 2002) . The use of stem cell-derived neurons in the clinic will require a more careful assessment of their properties. However, the production of dopamine neurons in the laboratory is not simply a logistical support for cell therapy. Dopamine neurons are of great interest in human behavior and psychiatry, ensuring a high interest in their synthesis from stem cells.
The second argument for continued interest in the ex vivo production of these cells is the unexpected finding that the mechanisms controlling the birth and death of adult dopamine neurons may be linked. Dopamine neurons are generated from an unusual source, the floor-plate. The floor-plate is specified by the transcription factor foxa2, and overexpression of foxa2 in ES cells boosts the production of dopamine neurons. In the adult brain, the transcription factor foxa2 is largely restricted to dopamine neurons, where it is central to their survival in old age (Kittappa et al., 2007) . Remarkably, the spontaneous degeneration of dopamine neurons in foxa2 +/À mice is similar to the dopamine neuron loss seen in PD patients, suggesting sensitive new assays to monitor early dysfunction. This animal model for spontaneous dopamine neuron loss in old age may provide new ways of probing the place of these cells in the hierarchy of disease progression and a new understanding of endogenous stressors. The relevance of these findings to PD may be assessed in neurons derived from pluripotent human cells.
Although these new insights into the birth and death of dopamine neurons are significant, the reports in Nature Medicine stress the value of tools that routinely monitor and manipulate the many other cell types showing disease pathology. Transplanting dopamine neurons, whether they are derived from the fetal brain or generated in the laboratory, seems an unlikely strategy to achieve a widespread effect. Of course, partial benefit would be acceptable, but simple strategies that reach all the affected cells might move us closer to addressing the distributed pathology seen in many degenerative disorders. Progress toward this goal would justify the world-wide interest in the stem cell field.
